Literature DB >> 10094281

Ehrlichiosis with severe pulmonary manifestations despite early treatment.

R A Weaver1, G Virella, A Weaver.   

Abstract

It is generally thought that if patients with ehrlichiosis are treated promptly, life-threatening illness can be avoided. We report a patient who sought medical attention 1 day after the onset of symptoms, was immediately given doxycycline, and still had serious illness with generalized edema, pulmonary infiltrates, acute respiratory distress syndrome, and noncardiogenic pulmonary edema, while receiving replacement intravenous fluids. This case alerts physicians to the serious end of the disease spectrum that can occur even though patients are given prompt, appropriate drug treatment at the onset of illness. Further studies are needed to clearly define the mechanisms involved in pulmonary complications and generalized edema, including noncardiogenic pulmonary edema, in patients with ehrlichiosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094281     DOI: 10.1097/00007611-199903000-00018

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  Animal model of fatal human monocytotropic ehrlichiosis.

Authors:  E A Sotomayor; V L Popov; H M Feng; D H Walker; J P Olano
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 2.  Ehrlichia chaffeensis: a prototypical emerging pathogen.

Authors:  Christopher D Paddock; James E Childs
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

3.  Fatal human monocytic ehrlichiosis: a case study.

Authors:  Joseph J Pavelites; Joseph A Prahlow
Journal:  Forensic Sci Med Pathol       Date:  2011-01-30       Impact factor: 2.456

4.  Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog.

Authors:  Marjolein Lisette den Toom; Tetyda Paulina Dobak; Els Marion Broens; Chiara Valtolina
Journal:  Acta Vet Scand       Date:  2016-07-07       Impact factor: 1.695

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.